Clinical Trial Search

Primary: Effect of MEDI-528 on Late Asthmatic Response (LAR) After Inhaled Allergen Challenge at Day 7 — 21.26; -16.21 Percent — p=0.168

Primary: Change From Baseline (Day -1) to Day 28 in Twenty-Four-Hour Weighted Average Glucose (24-Hour WAG) — -18.88; -11.95; -4.72; 8.52 mg/dL — p=0.006

Primary: Incidence of Adverse Events — 9; 9; 9; 9 Participants

Primary: Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of Prasugrel Active Metabolite (Pras-AM) — 8.68; 14.5; 20.8; 31.3 nanograms*hour per milliliter (ng*hr/mL)

Primary: Best Overall Response — 0; 14; 21; 8 Participants

Primary: Erythema Severity — 44.53 Erythema percent improvement

Primary: Objective Response to Treatment With Eribulin Mesylate in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer. — 2; 7; 16; 21 participants

Primary: Number of Nicotine Cigarette Choices Taken During the Cigarette Choice Procedure. — 18.5; 16.2 Number of Nicotine Cigarette Puffs Taken

Primary: Safety of CD34+ Stem Cell Infusions Followed by LLME as Measured by 100-Day Mortality — 1 participants

Primary: Number of Participants With Any Treatment-emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and AEs Leading to Discontinuation of at Least One Study…

Primary: 12-month Progression Free Survival (PFS) — 64.7 percentage of participants w/ 12 mo PFS

Primary: Adverse Events (AEs) — 10; 3; 6; 1 participants

Primary: Best Overall Response Rate (ORR) — 16.7; 23.7 % of participants w/ PR or better

Primary: Number of Participants With Unconfirmed Response (Complete Response or Partial Response) and Unconfirmed Complete Response — 437; 238 Participants

Primary: Change in Serum Alkaline Phosphatase Levels. — -57.3 U/L — p=0.001